The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis
Abstract
OBJECTIVE: To identify promising candidate genes linked to interindividual differences in the efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue to have relapses and worsening disability despite therapy. DESIGN: We used a genome-wide pharmacogenomic approach to identify single-nucleotide polymorphism (SNP) allelic differences associated with interferon beta therapy response. SETTING: Four collaborating centers in the Mediterranean Basin. Data Coordination Center at the University of California, San Francisco. PATIENTS: A cohort of 206 patients with relapsing-remitting MS followed up prospectively for 2 years after initiation of treatment. INTERVENTION: DNA was pooled and hybridized to Affymetrix 100K GeneChips. Pooling schemes were designed to minimize confounding batch effects and increase confidence by technical replication. MAIN OUTCOME MEASURES: Single-nucleotide polymorphism detection. Comparison of allelic frequencies between good responders and nonresponders to interferon beta therapy. RESULTS: A multianalytical approach detected significant associations between several SNPs and treatment response, which were validated by individual DNA genotyping on an independent platform. After the validation stage was complete, 81 additional individuals were added to the analysis to increase power. We found that responders and nonresponders had significantly different genotype frequencies for SNPs located in many genes, including glypican 5, collagen type XXV alpha1, hyaluronan proteoglycan link protein, calpastatin, and neuronal PAS domain protein 3. CONCLUSIONS: The reported results address the question of genetic heterogeneity in MS and the response to immunotherapy by analysis of the correlation between different genotypes and clinical response to interferon beta therapy. Many of the detected differences between responders and nonresponders were genes associated with ion channels and signal transduction pathways. The study also suggests that genetic variants in heparan sulfate proteoglycan genes may be of clinical interest in MS as predictors of the response to therapy. In addition to new insights into the mechanistic biology of interferon beta, these results help define the molecular basis of interferon beta therapy response heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · cited 1×
“05; the Benjamini-Hochberg method was used to correct for multiple comparisons.(17)”
MethodSkol, A. D., Scott, L. J., Abecasis, G. R., & Boehnke, M. (2006) · Nature Genetics · doi:10.1038/ng1706 · Cited by 1,286
Cited by
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
Baranzini, S. E., Wang, J., Gibson, R. A., Galwey, N., Naegelin, Y., Barkhof, F., Radue, E.-W., Lindberg, R. L. P., Uitdehaag, B. M. G., Johnson, M. R., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn388 · Cited by 476
Self-citationThe genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
Self-citationA Genomewide Association Study of Citalopram Response in Major Depressive Disorder
Garriock, H. A., Kraft, J. B., Shyn, S. I., Peters, E. J., Yokoyama, J. S., Jenkins, G. D., Reinalda, M. S., Slager, S. L., McGrath, P. J., & Hamilton, S. P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.029 · Cited by 288
Genome-wide association studies in pharmacogenomics
Daly, A. K. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2751 · Cited by 264
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Self-citation
Metadata
- Authors
- Byun, E., Caillier, S. J., Montalban, X., Villoslada, P., Fernández, O., Brassat, D., Comabella, M., Wang, J., Barcellos, L. F., Baranzini, S. E., & Oksenberg, J. R.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-03-01
- Volume
- 65
- Issue
- 3
- Pages
- 337-44
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2164238938
- Cited by
- 174
- References
- 3
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. https://app.cochat.ai/papers/10.1001/archneurol.2008.47
- The paper
- Byun, E., Caillier, S. J., Montalban, X., Villoslada, P., Fernández, O., Brassat, D., Comabella, M., Wang, J., Barcellos, L. F., Baranzini, S. E., & Oksenberg, J. R. (2008). Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology. https://doi.org/10.1001/archneurol.2008.47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.